VolitionRx Limited announces the launch of its Nu.Q(R) Vet Cancer Screening Test across the U.S. and the forthcoming launch in Europe by Heska Corporation, a leading global provider of advanced veterinary diagnostics, through Heska's veterinary diagnostic laboratories.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7276 USD | -2.01% | -5.51% | +1.48% |
14/05 | Transcript : VolitionRx Limited, Q1 2024 Earnings Call, May 14, 2024 | |
13/05 | VolitionRx Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.48% | 60.26M | |
-32.63% | 9.2B | |
-5.66% | 3.12B | |
+23.12% | 2.8B | |
-17.75% | 2.05B | |
-24.39% | 1.59B | |
+65.65% | 1.44B | |
+32.83% | 830M | |
-6.55% | 720M | |
-29.80% | 507M |
- Stock Market
- Equities
- VNRX Stock
- News VolitionRx Limited
- Volition Announces the Launch of the Nu.Q(R) Vet Cancer Screening Test in the U.S. and Europe Through Heska's Reference Laboratories